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Abstract
Background: Glioblastoma multiforme (GBM) is the most aggressive and frequent brain tumor, albeit without cure.
Although patient survival is limited to one year on average, significant variability in outcome is observed. The
assessment of biomarkers is needed to gain better knowledge of this type of tumor, help prognosis, design and
evaluate therapies. The neurodevelopmental polysialic acid neural cell adhesion molecule (PSA-NCAM) protein is
overexpressed in various cancers. Here, we studied its expression in GBM and evaluated its prognosis value for
overall survival (OS) and disease free survival (DFS).
Methods: We set up a specific and sensitive enzyme linked immunosorbent assay (ELISA) test for PSA-NCAM
quantification, which correlated well with PSA-NCAM semi quantitative analysis by immunohistochemistry, and thus
provides an accurate quantitative measurement of PSA-NCAM content for the 56 GBM biopsies analyzed. For
statistics, the Spearman correlation coefficient was used to evaluate the consistency between the
immunohistochemistry and ELISA data. Patients’ survival was estimated by using the Kaplan-Meier method, and
curves were compared using the log-rank test. On multivariate analysis, the effect of potential risk factors on the
DFS and OS were evaluated using the cox regression proportional hazard models. The threshold for statistical
significance was p = 0.05.
Results: We showed that PSA-NCAM was expressed by approximately two thirds of the GBM at variable levels. On
univariate analysis, PSA-NCAM content was an adverse prognosis factor for both OS (p = 0.04) and DFS (p =
0.0017). On multivariate analysis, PSA-NCAM expression was an independent negative predictor of OS (p = 0.046)
and DFS (p = 0.007). Furthermore, in glioma cell lines, PSA-NCAM level expression was correlated to the one of
olig2, a transcription factor required for gliomagenesis.
Conclusion: PSA-NCAM represents a valuable biomarker for the prognosis of GBM patients.
Background
Progress in GBM treatment has been limited. The dis-
ease is still characterized by a mortality rate approaching
100% and a lifespan of a few months from point of diag-
nosis. One of the main impediments to long-term survi-
val is recurrence despite resection of the primary tumor.
Recently, radiotherapy associated to adjuvant
Temozolomide chemotherapy has increased median sur-
vival to 14.2 months [1]. However, the development of
more efficient drugs as well as the use of more appro-
priate therapeutic protocols requires an improved
knowledge of the disease, at the molecular level. Mole-
cular diagnostics have emerged as a powerful tool to
discover new genes and therapeutic targets, and have
realized the proof of principle that personalized medi-
cine can increase survival and cure cancer patients [2].
Various genetic alterations have been identified in GBM,
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cancer Genome Atlas Research network: [3]]. However,
to date, the main significant prognosis factors evaluated
in large cohorts of patients are O6-methylguanine-DNA
methyl transferase promoter methylation status, age,
extent of resection, performance status, and mini mental
state examination [4].
Another focus of intense investigation has been the
existence and the role of cancer initiating cells (CIC) in
GBM [reviewed in [5]]. Although early studies have
focused on CD133 antigen as the CIC marker in GBM
[6], more recent studies have pointed out to the exis-
tence of CIC characterized by other cell surface markers
such as L1CAM [7] or the ganglioside A2B5 [8,9]. In
addition, some studies have shown the critical role of
olig2, a transcription factor expressed by normal oligo-
dendrocytes. We have reported that olig2 is expressed
by all human gliomas whatever their subtype and grade
[10], but its level is dramatically increased in highly pro-
liferative, tumorigenic GBM cell lines [11]. Furthermore,
olig2 seems to be required for gliomagenesis and prolif-
eration of neural progenitors [12].
We have postulated that PSA-NCAM could be a
powerful biomarker for human GBM. In fact, the spatio-
temporal pattern of expression of PSA-NCAM, a critical
parameter for proper neural morphogenesis, and its bio-
logical functions, are consistent with a possible role in
GBM. Indeed, polysialylation of NCAM is a broad feature
of growing CNS tissue in development, and it is a marker
specifically associated with proliferative and plasticity
events in adulthood [13,14]. PSA is a unique polymer of
a 2,8-N-acetyl neuraminic acid residues added to the
fifth Immunoglobulin domain of the membrane bound
NCAM. Importantly, by enabling limited cell-cell and
cell-extracellular matrix interactions [15], one hallmark
of PSA-NCAM is to favor cell migration, a critical feature
of the highly invasive behavior of GBM cells.
In order to investigate the expression and the putative
role of PSA-NCAM in GBM, we first set up a sensitive
ELISA test, which allowed specific detection above 10
pg PSA-NCAM/μg of protein. Results of the ELISA test
were correlated with immunohistochemical detection of
PSA-NCAM. We studied the expression of PSA-NCAM
in a series of 56 GBM samples and found PSA-NCAM
expression in 70% of them. Moreover, we report that
detectable PSA-NCAM by ELISA test (> 10 pg PSA-
NCAM/μg of protein) is an adverse factor of prognosis
associated with shorter OS and DFS. We then analyzed
PSA-NCAM expression in a human GBM cell line
GBM9, previously developed in our laboratory from a
patient biopsy and characterized by a highly proliferative
behavior and long term sphere formation [9]. We could
show that removing PSA-NCAM from these cells down-
regulated olig2. Conversely, PSA-NCAM forced expres-
sion in the C6 glioma cell line induced olig2 synthesis.
Methods
Human subjects and clinical parameters
Surgically resected samples were obtained from 56 adult
patients (age>18 years) from the Departments of Neu-
rooncology and Neurosurgery at the Marseille Hospitals
(AP-HM), in France from 1986 to 2005. All had primary
GBM, histologically proven according to the WHO clas-
sification, formalin fixed paraffin embedded tissue. The
frozen specimens were stored in the AP-HM tumor
bank (Authorization number 2008/70) with written
informed consent for tumor banking and study.
All patients benefited from surgery followed by radio-
therapy and alkylating agents chemotherapy (nitro-
sourea), and included long term survivors with a clinical
follow up of 8 years. Because the patients were treated
before 2005, none of them received the radiotherapy
associated to Temozolomide chemotherapy protocol
described by Stupp et al. [1].
For all patients, 26 males and 30 females, available clin-
ico-pathological data were the age, preoperative Kar-
nofsky performance status (KPS), extent of surgical
removal, OS and DFS. Mean age at diagnosis was 60.4
+/- 10.7, preoperative KPS was less than 70 in 21 patients
and greater than 70 in 35 patients. Total surgical excision
based on operative chart protocol was achieved in 39
patients and partial excision in 17 patients. The median
OS was 12.5 months [mean confidence interval (CI): 9.7-
15.4]. Of the 56 patients, 48 had relapse. The median
DFS was 6.7 months (mean CI: 4.2-9.2).
In addition, frozen specimens of 3 medulloblastomas
(MB) known to highly express PSA-NCAM [16], and
non tumorigenic adult brain tissues taken from a patient
biopsy in an area containing only non tumoral tissue
were used as controls. For PSA-NCAM immunohisto-
chemistry and ELISA analysis, cryostat sections from
each patient were checked and consisted of at least 60%
tumoral tissue and less than 40% necrotic or non
tumoral tissue.
PSA-NCAM immunohistochemistry
Anti-PSA-NCAM antibody (clone Men B2-2B dilution
1/500, Abcys, Paris, France) was applied on 5 μmc r y o -
stat sections available for all GBM and control cases.
Immunohistochemistry was performed on a Benchmark
XT (Ventana, Tucson, AZ, USA). Controls included
omission of primary antibody and abolition of the
immunostaining after endoneuraminidase N (endo N, 1/
1000; Abcys) treatment, which specifically cleaves alpha
2,8 linked acetyl neuraminic acid residues added to N
glycosylation sites on the fifth immunoglobulin domain
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semi-quantitative score. Briefly, the percentage of posi-
tive tumor cells per slide (0% to 100%) was multiplied
by the main intensity of staining (0: negative; 1: very
weak; 2: weak; 3: moderate; 4: intense). PSA-NCAM
expression score ranged from 0 to 320 in GBM. It was
up to 360 in MB.
Preparation of tissue and cell extracts, and protein
measurement for ELISA
Cells or tissues were homogenized in PBS, 0.1% Tri-
tonX-100 and sonicated. The nuclear and mitochondrial
fractions and debris were removed by centrifugation at
10000 g, 4°C, for 15 minutes. Total proteins were mea-
sured from the supernatant using the BCA kit (Perbio,
Brebieres, France). Samples were initially diluted in
phosphate buffered saline (PBS) at 37 μg/ml of protein
and tested in the ELISA assay. If necessary, the dilution
was adjusted to be in the linear range of the standard
curve, and the PSA-NCAM concentration calculated in
pg PSA-NCAM/μg of total protein.
Purification of PSA-NCAM for ELISA standard curve, and
of NCAM for anti-NCAM antibody generation
PSA-NCAM was purified from postnatal stage P0 mice
by affinity chromatography using the previously charac-
terized H28 monoclonal antibody [18] immobilized on
an Aminolink column (Perbio) at 10 mg/ml of resin,
according to the manufacturer’s procedure. Protein con-
centration was measured using the BCA kit.
NCAM was purified from adult mice brain on the
same affinity column, and used to produce a goat poly-
clonal anti-NCAM antibody (Eurogentec, Orleans,
France). The anti-NCAM recognizes the 3 main NCAM
isoforms (data not shown).
PSA-NCAM ELISA
Ninety six-well microtiter plates (Nunc Maxisorp,
VWR, Strasbourg, France) were coated with 100 μlo f
mouse monoclonal antibody directed against PSA-
NCAM (1/4000 in PBS) (Abcys). After PSA-NCAM
capture, the wells were washed 3 times with PBS
(Sigma, Lyon, France) and blocked with 200 μlo fP B S
containing 5% bovine serum albumin (BSA; Sigma) for
2ha t3 7 ° C .H u n d r e dμl of samples of unknown PSA-
NCAM concentration, and standards were then incu-
bated overnight at 4°C. Standards were prepared from
known amounts of PSA-NCAM purified from postna-
tal P0 mice as described above. The dose range for
PSA-NCAM standard curve was 0.25 to 16 ng/ml.
After 5 washes with PBS containing 0.1% Tween20
(PBST), wells were incubated with 100 μlo fg o a ta n t i
N-CAM prepared from purified mouse NCAM as
described above (1/4000; Eurogentec) in PBST, 5%
BSA (PBSTB) for 2 h at 37°C. After 5 washes with
PBST, wells were incubated with 100 μlo fd o n k e y
horseradish peroxidase (HRP)-coupled anti-goat anti-
body (Jackson Laboratory, Ban Harbor, MA) diluted
4000 times in PBSTB for 2 h at 37°C. Plates were
washed 5 times with PBST and incubated with 100 μl
of Tetramethylbenzidine (TMB; Sigma). TMB tablets
were diluted in 0.2 M dibasic sodium phosphate, 0.1
M citric acid, 0.6% H2O2. The reaction was stopped
with 100 μl1 . 8NH 2SO4. Absorbance was read at 450
nm using a 96-well plate reader (Berthold, Thoiry,
France) and the concentration of PSA-NCAM in sam-
ples was deduced from the standard curve.
For ELISA validation, the rhabdomyosarcoma TE671
cell line was used and grown as previously described
[17]. The specificity of the ELISA test was established
using endoN. A TE671 extract was digested with endoN
for 4 h at 37°C. Non digested and digested extracts were
serially diluted and tested in parallel in the same ELISA
test to ensure that the signal detected with the ELISA
was indeed specific for PSA-NCAM.
Cell culture, endoneuraminidase treatment and
immunocytochemistry
The rat C6 glioma cell line (ATCC-LGC, Molsheim,
France) was grown in Dulbecco’s modified Eagle’s med-
ium (DMEM) supplemented with 10% fetal calf serum
(FCS), penicillin (50 Units/ml) and streptomycin (100
μg/ml). The C6-PSA-NCAM cell line (generous gift of
M. Fukuda, The Burnham Institute for Medical
Research, La Jolla, CA) over expresses PSA-NCAM after
transfection with a polysialyltransferase construct (ST8-
SiaIV/PST) and has been previously described [19]. C6-
PSA-NCAM cells were grown in DMEM supplemented
with 10% FCS, penicillin, streptomycin and geneticin
(0.5 mg/ml). Both cell lines display similar proliferation
rates [20]. For olig2 quantification, 10 mm diameter
plates of C6 and C6-PSA-NCAM were used when cells
had reached confluence.
T h eG B M 9c e l ll i n ew a sd e s c r i b e di no u rp r e v i o u s
study [9]. Cells were grown as neurospheres in Neuro-
basal medium supplemented with B27, GlutaMAX™,
EGF (20 ng/ml) and bFGF (20 ng/ml), both from Pepro-
tech (London, UK). For splitting cells, spheres were
spun down (300 g, 5 minutes, RT) and dissociated with
1 to 2 ml Accumax (Abcys, Paris, France) for 30 min-
utes at 37°C. Single cells suspensions were obtained by
mechanical dissociation. Cells were subsequently spun
down and resuspended in growth medium. For differen-
tiation experiments, cells were plated in Poly-D-lysine
(10 μg/ml) coated multiwell-24 plates (30000 cells/well).
All cells were grown in humidified atmosphere contain-
ing 5% CO2 at 37°C. All tissue culture reagents were
from Invitrogen (Cergy Pontoise, Fance).
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tion, cells were treated with endoN (1/1000) for 3 days
in vitro. GBM9 cells were fixed with 4% paraformalde-
hyde for 15 minutes at room temperature (RT), and
washed with PBS. Cells were permeabilized with 0.1%
Triton X-100 and 3% BSA for 45 minutes. Primary anti-
bodies were incubated for 2 h at RT in PBS. Following 3
washes of 10 minutes each, appropriate secondary anti-
bodies were incubated for 1 h at RT. Nuclei were
stained with DAPI (0.5 μg/ml) for 5 minutes and
washed with PBS. Immunofluorescence staining was
observed using the Carl Zeiss Observer D1 inverted
microscope (Carl Zeiss, Gottigen, Germany) equipped
with a 20 × objective. The following antibodies were
used: olig2 (rabbit IgG, 1/1000; Abcys), GFAP (mouse
IgG, 1/1000; Millipore, Molsheim, France), b3-tubulin
(mouse IgG, 1/1000; Sigma), Nestin (mouse IgG, 1/500;
Abcys), PSA-NCAM (mouse IgM, 1/1000; Abcys),
Alexa555-anti-mouse IgG, CY3-anti-mouse IgM,
Alexa488-anti-rabbit IgG (all 1/500; Jackson Laboratory).
Western Blot
C6 and C6-PSA-NCAM total cell extracts were prepared
by scraping cells in 500 μlo f1 0m MT r i s H C lp H7 . 4
containing 0.1% TritonX-100 and Complete™ protease
inhibitors (Roche, Mannheim, Germany) followed by
sonication. Proteins were run on an 8% SDS-polyacryla-
mide gel. Western blot was performed according to
standard protocols with anti-olig2 (1/4000), anti-PSA-
NCAM (1/1000), and anti-a-tubulin (mouse IgG, 1/
2000, Sigma). Secondary antibodies were coupled to
HRP (1/20000; Jackson Laboratory).
Statistical analysis
The percentage of olig2 positive cells in GBM9 differen-
tiation assay was analyzed using contingency tables fol-
lowed by the Fisher’s exact test. The Spearman
correlation coefficient was used to evaluate the consis-
tency between the 2 methods of PSA-NCAM content
measurements in biopsies (immunohistochemistry and
ELISA).
For statistics performed on GBM patients, the SPSS
15.0 software for windows (SPSS Inc, Chicago, Illinois,
USA) was used. Survival was estimated using the
Kaplan-Meier method, and curves were compared using
the log-rank test. On multivariate analysis, the effect of
potential risk factors including age (< 60 versus ≥ 60),
preoperative KPS (< 70 versus ≥ 70), extent of surgical
excision (partial versus total), and PSA measurement
by ELISA (≤ 10 pg PSA-NCAM/μg of protein versus
>1 0p gP S A - N C A M / μg of protein) on the DFS and OS
were evaluated using the cox regression proportional
hazard models. The threshold for statistical significance
was p = 0.05.
Results
PSA-NCAM ELISA sensitivity, linearity and specificity
We developed a sandwich ELISA to detect PSA-NCAM
by taking advantage of the monoclonal anti-PSA-NCAM
developed in our laboratory [21] (Abcys) as the capture
antibody. An anti-mouse NCAM was then produced by
immunizing goats with NCAM purified from adult mice
brain, and used as the detection antibody.
A linear relationship could be established between
known amounts of PSA-NCAM and optical density
readings between 0.25 and 16 ng PSA-NCAM/ml (Fig-
ure 1A). Tissue extracts were tested after dilution at 37
μg of protein/ml; therefore the corresponding limit of
detection in such sample is 6.75 pg PSA-NCAM/μgo f
protein. The test was linear over 2 logs around the con-
centration tested. Intra-assay coefficient of variation was
less than 5% (n = 3). Although the ELISA was designed
with appropriate antibodies to detect PSA-NCAM, we
Figure 1 Standard curve of PSA-NCAM ELISA.( A )I n c r e a s i n g
amounts of purified PSA-NCAM from P0 mouse brains were
detected by the developed ELISA. Data are presented as mean +/-
standard deviation of duplicate measurements. (B) ELISA test on
serial dilutions of TE671 extract expressing PSA-NCAM or treated
with endoN.
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PSA-NCAM from an extract of TE 671 cells known to
express PSA-NCAM [17]. After verifying that endoN
indeed digested PSA-NCAM by Western blot (not
shown), a serial dilution of TE671 extract treated or not
with endoN was prepared and tested by ELISA. Data
shown on Figure 1B indicate that the signal obtained in
absence of endoN is specific for PSA-NCAM as it was
completely abolished at most dilutions of the extract
after enzymatic digestion. In these diluted extracts, PSA-
NCAM was more concentrated than in the GBM biop-
sies, ensuring that the signal measured in GBM biopsies
was entirely PSA-NCAM specific. However, a limitation
of our test is that although the anti-PSA antibody allows
to reveal PSA, it does not discriminate between different
lengths of PSA chains. In order to accurately assess
PSA-NCAM level from GBM biopsies, its expression in
normal brain tissue had to be determined. Adult human
brain cortex expresses PSA-NCAM only on rare cells
[22]. In non tumoral adult human brain tissue, a signal
equivalent to 8 pg PSA-NCAM/μg of protein was mea-
sured, and PSA-NCAM was below detection in adult
mouse cortical tissues (n = 4). Moreover, the inter assay
variability for these samples was of 10 pg/μgo fp r o t e i n .
Therefore, the threshold of significance for specific
detection of PSA-NCAM was set to 10 pg PSA-NCAM/
μg of protein. This value was chosen to classify groups
of GBM patients that express either less or more than
10 pg PSA-NCAM/μg of protein.
Embryonic human brain extract served as positive
control since it is known to express high level of PSA-
NCAM, as do medulloblastoma (MB) tissues [16], which
was confirmed in the current study by immunohisto-
chemistry (Figure 2C) and ELISA for MB (150-1030 pg
PSA-NCAM/μg of protein, n = 3) and embryonic
human brain (1600 pg PSA-NCAM/μg of protein).
PSA-NCAM measurement by ELISA is correlated to
immunohistochemistry analysis
Immunohistochemistry has been so far the standard
method in anatomopathology laboratories, including
using the PSA-NCAM antibody [16,23]. Therefore, we
verified that the results obtained using the ELISA test
correlated with the immunohistochemistry results.
Figure 2A shows biopsies with various degrees of PSA-
NCAM immunohistochemistry staining with the corre-
sponding ELISA measurements. They illustrate weak or
medium PSA-NCAM immunostaining in two GBM
Figure 2 PSA-NCAM measurements by immunohistochemistry and ELISA, and distribution of PSA-NCAM measurement by ELISA in 56
GBM biopsies. PSA-NCAM immunohistochemistry on two GBM biopsies with below detection (A) or positive (B) staining, and on a MB biopsy
highly expressing PSA-NCAM (C); scale bar: 33 μm. (D) Individual measurements of PSA-NCAM in the 56 GBM, by ELISA and
Immunohistochemistry. (E) Individual measurements of PSA-NCAM by ELISA and Immunohistochemistry in two groups (PSA-NCAM<10 pg/μgo f
protein and PSA-NCAM>10 pg/μg of protein). Lines indicate the median in each group (F) Distribution of PSA-NCAM content from 56 biopsies,
represented as boxplot with first quartile (9 pg PSA-NCAM/μg of protein), median (25 pg PSA-NCAM/μg of protein) and third quartile (40 pg
PSA-NCAM/μg of protein). The dotted line corresponds to 10 pg PSA-NCAM/μg of protein (level of sensitivity of PSA-NCAM detection in GBM
tissue).
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value by ELISA, similar to non-tumoral adult human
b r a i nt i s s u ef o rG B M 1( F i g u r e2 A )a n dh i g h e rf o r
GBM2 (Figure 2B). It is worth noticing that PSA-
NCAM expression was different from one GBM to
another: either weak and diffuse in large area of the
biopsy in some cases (Figure 2B), or strong but
restricted to fewer tumor cells in others (Figure 2A),
this last pattern of expression being more frequent. We
also included in our study 3 MB known to express high
levels of PSA [16]. These MB samples were highly
stained by immunohistochemistry (score 360 to 400)
(Figure 2C) and displayed high PSA-NCAM concentra-
tions by ELISA (150-1030 pg PSA-NCAM/μg of protein,
n = 3). In total, a series of 56 GBM samples were ana-
lyzed by immunohistochemistry and given a score, and
by ELISA. Figure 2D shows the 56 individual values of
PSA-NCAM measured by ELISA and immunohisto-
chemistry, and on Figure 2E, patients were separated in
two groups (ELISA PSA-NCAM <10 pg/μgo fp r o t e i n
and PSA-NCAM >10 pg/μg of protein). Spearman cor-
relation test shows a statistical positive correlation
between the two methods of PSA-NCAM measurement
(Rho = 0.439, p = 0.005).
PSA-NCAM is expressed in 70% of 56 GBM biopsies
We quantified PSA from 56 GBM biopsies. As much as
7 0 %o ft h e me x p r e s s e dP S A - N C A Ma tl e v e l sa b o v e1 0
pg PSA-NCAM/μg of protein. The median was of 24.73
pg PSA-NCAM/μg of protein. Apart from some very
high values as depicted on the histogram (Figure 2F),
50% of the biopsies gathered around the median. It
should be noted that 90% of them contained less PSA-
NCAM than the MB with the lowest PSA-NCAM con-
tent (150 pg PSA-NCAM/μg of protein).
PSA-NCAM expression in GBM is correlated to shorter OS
and DFS
In this series, none of the clinical factors including age,
preoperative KPS and extent of surgical removal was
correlated to OS or DFS. The patient cohort includes
long-term survivors, and surgical resection was not sys-
tematically analyzed by MRI. These factors could have
prevented to reveal the prognosis value of these classical
clinical parameters. However, PSA-NCAM expression
was significantly associated to OS [median OS: 20.8
months (CI:14.2-27.4) in patients with PSA-NCAM
GBM content ≤ 10 pg/μg of protein versus 12.2 months
(CI:11.0-13.5) in the others; p = 0.04, n = 56] (Figure
3A). PSA-NCAM expression was also statistically corre-
lated to DFS (median DFS: 11.2 months (CI:7.6-14.8) in
patients with PSA-NCAM GBM content ≤ 10 pg/μgo f
protein versus 6 months (CI:3.4-8.5) in the others; p =
0.017, n = 54] (Figure 3B).
On multivariate analysis (age, KPS and extent of surgi-
cal excision), PSA-NCAM expression was the unique
predictive parameter of OS [hazard ratio (HR): 2.01 for
patients suffering from a GBM with PSA-NCAM con-
tent >10 pg/μg of protein (CI:1.01-4); p = 0.046, n = 56]
and DFS [HR: 2.89 for patients suffering from a GBM
with PSA-NCAM content >10 pg/μg of protein (CI:1.34-
6.27); p = 0.007, n = 54].
PSA-NCAM regulates olig2 expression in glioma
To further elucidate the role that PSA-NCAM could
play in GB, we investigated whether PSA removal using
endoN affected the properties of the GBM9 cell line we
previously developed and characterized as a highly pro-
liferative neurosphere forming cell line [9]. To this end
we compared features of endoN treated and non treated
cells in different culture conditions. In basal conditions,
cells were grown in presence of EGF and FGF [9]. In a
representative experiment described on Figure 4, out of
two performed, 88% of the GBM9 cells expressed the
olig2 transcription factor. Representative pictures taken
from at least 5 independent fields are shown on Figure
4A. Under conditions of PSA removal, the percentage of
olig2 positive cells decreased to 64% (Figure 4B). If EGF
a n dF G Fw e r er e m o v e df r o mt h ec u l t u r em e d i u m ,5 2 %
of the cells were olig2 positive, and this percentage
further decreased to 35% after PSA digestion. The mean
of at least 5 fields is represented on Figure 4B. In the
two experiments performed, the percentage of cells los-
ing olig2 was 30 and 46% in the presence of EGF and
FGF, and 17 and 35% in the absence of growth factors,
respectively. PSA removal was capable of decreasing sig-
nificantly olig2 content in this GB cell line both under
proliferative conditions in the presence of EGF and FGF
( p=0 . 0 1 5 3a n dp=0 . 0 3 9 9f o rt h e2e x p e r i m e n t s ,
respectively), and in their absence (p = 0.0289 and p =
0.0297 for the 2 experiments, respectively). We found
no effect of PSA removal on the percentage of other cell
lineages generated (GFAP
+ astrocytes, b3-tubulin
+ neu-
rons or Nestin
+ progenitors) neither in presence, nor in
absence of growth factors (not shown).
To uncover a possible causal relationship between
olig2 and PSA expression,w et e s t e dw h e t h e rP S A -
NCAM gain of function would affect olig2 expression.
We chose C6 cells which displayed undetectable PSA-
NCAM by ELISA or Western blot and show many fea-
tures of GB tumors after intracranial injection such as
an undifferentiated morphology [20], neovascularization
[24], diffuse infiltrating borders and invasion of the sur-
rounding tissue by isolated cells [25]. Moreover, PSA-
NCAM forced expression in these cells has been shown
to be associated with their increased migration when
transplanted in mice [20]. Therefore, we compared olig2
content in PSA-NCAM negative C6, and C6-PSA-NCAM
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measured by ELISA. Whereas C6 cells did not express
olig2, C6-PSA-NCAM displayed strong olig2 expression
indicating that in these cells, forced expression of PSA
is sufficient to induce olig2 as shown by western blot
analysis in Figure 4C.
Discussion
In the current study, we show that PSA-NCAM is a
prognosis factor in GBM, by using a new ELISA assay
for PSA-NCAM. This test allows quantifying accurately,
specifically, and with high sensitivity PSA-NCAM on
small amounts of biopsy materials. The results obtained
were well correlated to immunohistochemistry analysis,
showing the robustness of the assay. However, some
samples displayed different levels of PSA, depending on
the method of measurement. The non-linear scoring by
IHC and the possible heterogeneity of the tumor may
partly explain the discrepancy between the two methods.
High PSA values by ELISA could therefore represent
false positives (type I error) as their IHC score was 0 in
the PSAELISA >10 pg/μg of protein group (12 cases), or
false negatives (type II error) as their IHC value was
much higher than the median IHC score in the
Figure 3 PSA-NCAM is negatively correlated to overall (OS) and disease free (DFS) survival. Survival curves of patients from the two
groups: PSA-NCAM>10 pg/μg of protein (n = 39 for OS; n = 38 for DFS) and PSA/NCAM ≤ 10 pg/μg of protein (n = 17 for OS; n = 16 for DFS).
(A) OS: Kaplan-Meier curves indicate for each time point the proportion of patients still alive at that time. (B) DFS: Kaplan-Meier curves indicate
for each time point the proportion of patients that did not yet have a relapse at that time. (+): censored patients.
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theless, when confronted with the outcome of patients,
the ELISA measurement of these samples seemed to be
more predictive. Three out of the 4 samples that had
low PSA by ELISA came from patients that had an over-
all survival > 20.8 months (median OS in the PSAELISA
<10 pg/μg of protein group) and disease free survival >
11.2 months (median DFS in the PSAELISA <10 pg/μgo f
protein group). Nine out of the 12 samples that had
high PSA by ELISA came from patients that had
an overall survival < 12.2 months (median OS in the
PSAELISA >10 pg/μg of protein group) and disease free
survival <6 months (median DFS in the PSAELISA >10
pg/μg of protein group).
Importantly, this test presents a number of advantages
over currently in use measurement techniques, immuno-
histochemical detection and Western blot, which are
semi-quantitative. Therefore, once validated on a larger
scale, it fulfills the criteria (quantitative test, sensitivity
and specificity) that would allow its use in the clinic for
GBM and other cancers. Indeed, in addition to the
prognosis value of PSA-NCAM in GBM demonstrated
here, evidence from our and others’ studies have shown
that PSA-NCAM is also a reliable marker in many types
of cancers of the CNS and other organs, and that it is
involved in the process of metastasis [16,23,26-28]. A
correlation could also be established between the level
of PSA-NCAM and the severity of the disease and/or
Figure 4 Olig2 is positively correlated to PSA-NCAM. (A) Immunostaining of GBM9 cells with anti-olig2 (green, Alexa488) and anti-PSA-NCAM
(red, CY3) in the presence of EGF + FGF (a), EGF + FGF + endoN (b), no growth factor (c), endoN and no growth factor (d). Cells were
counterstained with DAPI (blue); scale bar: 20 μm. (B) Quantification of immunostaining described above from a representative experiment out
of 2 performed. Percentage of olig2
+ cells is presented as mean +/- standard deviation of the percentage of olig2
+ cells grown in presence of
EGF and FGF, from at least 5 independent fields of view per condition. Between 174 and 571 cells per condition were counted. (*: p < 0.05,
***: p < 0.001; Fisher’s test). (C) Representative western blot out of 3 independent cultures of C6 and C6-PSA-NCAM with anti-PSA-NCAM, anti-a-
tubulin and anti-olig2 antibodies.
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of cancer including medulloblastoma [28], neuroblas-
toma [29], rhabdomyosarcoma [30] and small cell lung
carcinoma [31]. PSA-NCAM in non-small cell lung can-
cer biopsies was correlated with tumor progression and
was an independent prognosis factor [32]. NCAM
expression has also been evaluated in glioma [20], and
other tumor types [31], but NCAM immunoreactivity
does not differentiate polysialylated from non polysialy-
lated NCAM. Interpretations of NCAM expression
results have therefore been limited due to the omitted
consideration of NCAM polysialylation, post-transla-
tional modification that affects dramatically NCAM
binding properties and intermembrane repulsion [15].
In gliomas, PSA-NCAM has been detected in GBM
explants [33] and on biopsies more frequently in diffuse
astrocytoma cells, which spread extensively [20]. It has
also been shown to confer invasive properties to glioma
cells in animal models [20]. However, although some
studies have reported biomarkers of different grades of
glioma [34,35], investigations showing the prognosis
value of molecular factors by multivariate analysis, speci-
fically in the GBM subgroup, have been limited, and
most used semi-quantitative methods or mRNA analysis
[36,37]. Therefore, the methodology developed here and
the finding of PSA-NCAM as a prognosis marker in
GBM appears significant.
We found that 70% of biopsies expressed PSA-NCAM
at levels above the level set up as background, with
some variability. Moreover, GBM showed considerably
lower levels than MB. A likely explanation for this dif-
ference is that MB cells are all in the same differentia-
tion state, engaged in a neuronal phenotype, whereas in
GBM, cells from very immature to differentiated pheno-
type can be observed (personal observations). The con-
trasted low PSA levels in GBM versus high levels in MB
could also explain the highly metastatic versus non
metastatic behavior of MB versus GBM, respectively.
The content of PSA-NCAM in GBM biopsies might
result from at least two phenomena: the number of cells
expressing PSA-NCAM and the amount of PSA-NCAM
expressed by individual cells. The different patterns of
PSA-NCAM expression observed by immunohistochem-
istry in GBM are in keeping with these hypotheses as
some show a rather low level on many cells spread over
the tissue whereas for others high expression is exhib-
ited only by islets of cells. However, since the tumor is
not strictly homogeneous, the different staining patterns
that can be observed cannot be assumed to be respre-
sentative of the entire tumor of a given patient. Cells
expressing PSA-NCAM could be either progenitors and/
or cells exhibiting an altered differentiation process due
to transformation, although we cannot exclude that in
some cases PSA-NCAM positive cells are cells from the
subventricular zone attracted by the tumor [38]. PSA
expression is under transcriptional control, a mechanism
that can be perturbed following oncogenic transforma-
tion, and the enzymes polysialyltransferases that transfer
PSA to NCAM represent obvious targets. In addition,
several post-translational mechanisms that have been
shown to regulate the expression dynamics could be at
play [39,40].
Despite variations of expression, PSA-NCAM expres-
sion was correlated with poor prognosis for both OS
and DFS. Although at this stage whether PSA-NCAM
molecule itself plays a causal role or is a downstream
consequence of changes in tumorigenesis is not known,
some hypotheses may be formulated to explain a nega-
tive role of PSA-NCAM in survival. First, PSA-NCAM
may be carried by undifferentiated cells in the tumor
capable of cancer initiation and resistance to therapy
[7]. Indeed, cumulative studies suggest that persistence
of PSA-NCAM could prevent differentiation. During
development, a defined spatial and temporal window of
expression of PSA-NCAM illustrates that this molecule
constitutes a very effective cue when plasticity and pre-
cise timing of differentiation is required [40]. A promi-
nent role of PSA in differentiation is also supported by
its capacity to delay oligodendrocyte maturation events
such as differentiation and myelinating potential
[19,41,42] or neuronal differentiation [43,44]. Moreover,
PSA-NCAM is an attractive candidate to be expressed
by CIC since it is characterized by a strong and ubiqui-
tous expression during embryonic development in mul-
tipotent or lineage restricted precursors, and a stem cell
niche marker in the adult CNS, mainly in the SVZ and
hippocampus producing neuroblasts throughout life.
Polysialylation could therefore support the maintenance
of an immature phenotype. Transplantation studies with
PSA
+ and PSA
- GBM cell populations will be required
to answer whether PSA-NCAM defines cell populations
with CIC properties.
Second, PSA-NCAM could favor infiltration of cells in
t h es u r r o u n d i n gh e a l t h yt i s s u ea n db er e s p o n s i b l ef o r
earlier relapse, which may subsequently lead to
decreased OS as disseminated tumor cells play a critical
role in GBM recurrence. This PSA-NCAM enhancing
effect on migration was indeed demonstrated in healthy
tissue and in disease models such as rhabdomyosarcoma
metastasis mouse model [27] and after grafting of PSA-
expressing C6 glioma cells in mouse brain [20].
Third, PSA-NCAM might trigger proliferation and
enhance GBM growth. This could occur via an
increased sensitivity of PSA-NCAM positive cells to
growth factors such as PDGF, as shown for oligodendro-
cytes [45], or GDNF [17]. Interestingly PDGF receptor
expression was required for oligodendrocytes to gener-
ate gliomas [46]. An alternative could be the prevention
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in astrocytes [47] or neuroblastoma cell lines [48].
Importantly, we also found olig2 expression to be
regulated by PSA-NCAM expression in the GBM9 cell
line or to be activated in C6 after PSA-NCAM expres-
sion. The mechanisms underlying olig2 regulation could
be related to PSA-NCAM mediated alterations of cell
proliferation, survival or differentiation [19,41-44,48]
and remain to be elucidated. Olig2 has been described
as a negative regulator of astrocytic differentiation path-
way [49], to be required for gliomagenesis and to be
coupled to an inhibition of the antiproliferative p21
pathway [12]. Olig2 is also known to play an important
role in proliferation and fate determination in the devel-
opment of the nervous system and adulthood [50].
Therefore, one of the consequences of PSA-NCAM up
regulation in GBM could be olig2 increase and its
downstream growth and differentiation consequences.
Further investigations of the impact of olig2 levels in
relation to GBM patients’ survival appear compelling.
In conclusion, PSA-NCAM is another example of
molecules having a dual role, during development as
fundamental regulators of pattern formation and differ-
entiation, and in cancer. Moreover, the role of an adhe-
sion molecule of the immunoglobulin family in cancer
stem cell is not unprecedented since L1CAM was
recently shown to be required to suppress glioma
growth of CD133
+ cells in vitro and in vivo [7]. These
findings constitute the first evidence that PSA-NCAM
expression correlates with GBM patient survival. This
novel biomarker for GBM may represent an interesting
molecular tool for diagnosis and prognosis in clinical
use. This may also have important clinical implications
for the treatment of GBM patients as previously sug-
gested with chemicals that alter PSA expression with
the goal to modulate polysialylation in tumors [51]. This
study warrants further investigation of PSA-NCAM with
regard to response to treatment in future prospective
studies on a larger number of GBM patients.
Conclusions
We present PSA-NCAM as a new candidate prognosis
biomarker for GBM. It represents immediate valuable
information to improve life conditions of patients and
clinical decisions, and represents a prospective therapeu-
tic target and stratifying factor for clinical trials. This
novel finding, next to the negative impact of PSA-
NCAM on survival and metastasis in other cancers,
emphasizes a critical and general role of PSA-NCAM in
cancer evolution. The new ELISA test described in the
current study was characterized as an accurate and spe-
cific quantitative mean to measure PSA-NCAM from a
small amount of biopsy, and therefore is a powerful
tool, notably for validationi nal a r g e rp a t i e n tc o h o r t ,
but also to investigate PSA-NCAM with regard to
response to treatment. In addition, this new ELISA test
can be applied to all tumors expressing PSA-NCAM.
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